Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 16/20 | 1.00 |
| ▸ | GSK3B | P49841 | 2/20 | 0.63 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1648440 | 1.00 | BACE1 (1.00) | BACE1GSK3BABCG2NPC1RAB9A | |
| SCHEMBL1646226 | 0.90 | BACE1 (0.82) | BACE1GSK3BSMN1; SMN2 | |
| SCHEMBL1646231 | 0.90 | BACE1 (0.82) | BACE1GSK3BSMN1; SMN2 | |
| SCHEMBL1648388 | 0.88 | BACE1 (0.79) | BACE1GSK3BSMN1; SMN2 | |
| SCHEMBL1648392 | 0.88 | BACE1 (0.79) | BACE1GSK3BSMN1; SMN2 | |
| SCHEMBL1648284 | 0.87 | BACE1 (0.77) | BACE1GSK3BNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1647408 | 0.87 | BACE1 (0.77) | BACE1GSK3BRAB9A | |
| SCHEMBL1647409 | 0.87 | BACE1 (0.77) | BACE1GSK3BRAB9A | |
| SCHEMBL1648289 | 0.87 | BACE1 (0.77) | BACE1GSK3BNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1648577 | 0.85 | BACE1 (0.74) | BACE1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962674-B2 | Curcumin derivative | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2015-02-24 | — | — | US | disclosed |
| US-8552220-B2 | Therapeutic agent for Alzheimer's disease | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2013-10-08 | — | — | US | disclosed |
| US-20110082295-A1 | NOVEL CURCUMIN DERIVATIVE | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2011-04-07 | — | — | US | disclosed |
| EP-2305629-A1 | THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | Tokyo Institute of Technology (JP) | 2011-04-06 | — | — | EP | disclosed |
| US-20100048901-A1 | NOVEL CURCUMIN DERIVATIVE | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2123637-A1 | NOVEL CURCUMIN DERIVATIVE | Tokyo Institute of Technology (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048901-A1 | NOVEL CURCUMIN DERIVATIVE | BACE1, APP, BACE2 | BACE1 1/4885GSK3B 851/4885ABCG2 3722/4885 |
| US-20110082295-A1 | NOVEL CURCUMIN DERIVATIVE | BACE1, APP, BACE2 | BACE1 1/4885GSK3B 1197/4885ABCG2 1840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.